Hospital
Shelby County Health Care Corporation
Shelby County Health Care Corporation was paid $56.20M by Medicaid between Jan 2018 and Dec 2024, across 312 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 25% of everything it billed.
33Billing provider infoSHELBY COUNTY HEALTH CARE CORPORATION
MEMPHIS, TN 38103
MEMPHIS, TN 38103
33aNPI1144213117assigned 08/25/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$56.20M
24GClaims1,793,671
24DCodes billed312
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Tennessee
Rank by total paid#1 of 71
Median peer was paid$6.96M
This provider vs. median8.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 285,215 | $8.94M | |
| 2019 | 275,660 | $9.59M | |
| 2020 | 247,817 | $7.93M | |
| 2021 | 268,125 | $7.47M | |
| 2022 | 264,653 | $8.13M | |
| 2023 | 277,546 | $8.73M | |
| 2024incomplete | 174,655 | $5.41M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 25% | 333,922 | 278,180 | $14.04M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 38,011 | 32,118 | $12.31M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 43,859 | 38,051 | $9.04M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 12,689 | 10,041 | $5.92M |
| 59025 | Fetal non-stress test | 1.8% | 8,605 | 6,502 | $1.03M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.6% | 17,953 | 16,293 | $884K |
| G0378 | Hospital observation service, per hour | 1.4% | 6,566 | 1,830 | $794K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 5,080 | 4,453 | $696K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 103,334 | 78,275 | $593K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,900 | 4,313 | $446K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 3,126 | 2,891 | $408K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 5,028 | 4,724 | $407K |
300 more codes
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 4,887 | $399K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 22,527 | $348K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 4,355 | $299K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 3,131 | $261K |
| 36415 | Collection of venous blood by venipuncture | <1% | 124,121 | $258K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 69,066 | $238K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 14,208 | $236K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 10,270 | $228K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 10,111 | $221K |
| 83735 | <1% | 52,365 | $216K | |
| 84484 | <1% | 15,743 | $212K | |
| 87536 | <1% | 13,831 | $208K | |
| 36512 | <1% | 879 | $207K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 14,130 | $196K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,577 | $185K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,848 | $184K |
| 86885 | <1% | 14,634 | $176K | |
| 80053 | Comprehensive metabolic panel | <1% | 54,105 | $164K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,853 | $164K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,167 | $163K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 9,532 | $162K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 2,874 | $151K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12,744 | $147K |
| 86900 | <1% | 14,790 | $132K | |
| 85027 | <1% | 36,394 | $129K | |
| 81025 | <1% | 27,451 | $128K | |
| 90461 | <1% | 6,756 | $125K | |
| 83605 | <1% | 16,613 | $121K | |
| 86901 | <1% | 14,972 | $118K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,906 | $110K |
| 84100 | <1% | 44,311 | $109K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 19,635 | $108K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 4,631 | $106K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 8,096 | $104K |
| 71045 | Radiologic examination, chest; single view | <1% | 14,041 | $100K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,494 | $95K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,388 | $93K |
| 86360 | <1% | 7,637 | $89K | |
| Q3014 | Telehealth originating site facility fee | <1% | 6,071 | $88K |
| 82947 | <1% | 22,300 | $88K | |
| 86359 | <1% | 7,686 | $87K | |
| 80076 | <1% | 28,317 | $84K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 3,380 | $83K |
| 81003 | <1% | 43,774 | $80K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,841 | $78K |
| 11721 | <1% | 5,144 | $76K | |
| 76801 | <1% | 1,153 | $71K | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 8,389 | $68K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 4,282 | $65K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,938 | $60K |
| 87340 | <1% | 12,205 | $58K | |
| 29581 | <1% | 2,518 | $58K | |
| 97597 | <1% | 1,142 | $56K | |
| 90686 | <1% | 6,504 | $56K | |
| 82962 | <1% | 23,104 | $51K | |
| 86592 | <1% | 21,038 | $51K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 5,726 | $50K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,300 | $48K |
| 96367 | <1% | 1,683 | $47K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,686 | $45K |
| 80061 | Lipid panel | <1% | 11,701 | $44K |
| 86803 | <1% | 6,201 | $44K | |
| 83690 | <1% | 8,883 | $41K | |
| 86902 | <1% | 3,460 | $40K | |
| 36430 | <1% | 1,082 | $35K | |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 486 | $33K |
| 73610 | <1% | 2,313 | $31K | |
| 73552 | <1% | 1,751 | $31K | |
| 84703 | <1% | 5,097 | $31K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 237 | $31K |
| 80047 | <1% | 4,002 | $28K | |
| 76818 | <1% | 373 | $28K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 391 | $28K |
| 83880 | <1% | 2,946 | $27K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13,640 | $27K |
| 86920 | <1% | 1,286 | $26K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,414 | $24K |
| 88184 | <1% | 6,168 | $23K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 150 | $23K |
| 96160 | <1% | 1,980 | $23K | |
| 85610 | <1% | 8,670 | $23K | |
| 73590 | <1% | 1,707 | $22K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,548 | $22K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 251 | $22K |
| 11720 | <1% | 741 | $20K | |
| 73560 | <1% | 1,410 | $20K | |
| 76820 | <1% | 431 | $19K | |
| 76821 | <1% | 422 | $18K | |
| 81001 | <1% | 17,642 | $18K | |
| 85018 | <1% | 6,772 | $17K | |
| 82728 | <1% | 7,672 | $17K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 596 | $17K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 123 | $17K |
| 92550 | <1% | 878 | $17K | |
| 72190 | <1% | 886 | $16K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 611 | $16K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,960 | $16K |
| 88185 | <1% | 6,191 | $15K | |
| 83020 | <1% | 4,416 | $15K | |
| 85660 | <1% | 4,908 | $15K | |
| 84702 | <1% | 939 | $15K | |
| 86762 | <1% | 2,300 | $14K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,340 | $14K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 630 | $13K |
| 86480 | <1% | 1,109 | $13K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 608 | $13K |
| 90715 | <1% | 488 | $13K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 55 | $12K |
| 52000 | <1% | 47 | $12K | |
| 11056 | <1% | 1,669 | $12K | |
| 70496 | <1% | 114 | $12K | |
| 70498 | <1% | 114 | $12K | |
| 85014 | <1% | 7,412 | $12K | |
| 86922 | <1% | 1,430 | $11K | |
| 82565 | <1% | 2,471 | $10K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,106 | $9K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 42 | $9K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 227 | $8K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 38 | $8K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 305 | $8K |
| 85730 | <1% | 1,421 | $8K | |
| 87081 | <1% | 1,910 | $7K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,318 | $7K |
| 73630 | <1% | 596 | $7K | |
| 85045 | <1% | 6,590 | $7K | |
| 82550 | <1% | 1,269 | $6K | |
| 90670 | <1% | 177 | $6K | |
| 86140 | <1% | 4,043 | $6K | |
| 87210 | <1% | 1,501 | $6K | |
| 83550 | <1% | 3,799 | $6K | |
| 90677 | <1% | 54 | $5K | |
| 73130 | <1% | 416 | $5K | |
| 51798 | <1% | 129 | $5K | |
| 76827 | <1% | 120 | $5K | |
| 99201 | <1% | 349 | $5K | |
| 82570 | <1% | 1,251 | $5K | |
| G0008 | Administration of influenza virus vaccine | <1% | 2,232 | $5K |
| 99205 | Prolong outpt/office vis | <1% | 71 | $5K |
| 76770 | <1% | 122 | $5K | |
| 11719 | <1% | 291 | $5K | |
| 87077 | <1% | 958 | $5K | |
| 94760 | <1% | 592 | $4K | |
| 83540 | <1% | 3,807 | $4K | |
| 92551 | <1% | 428 | $4K | |
| 83970 | <1% | 669 | $4K | |
| 96127 | <1% | 840 | $4K | |
| 73562 | <1% | 478 | $4K | |
| 36416 | <1% | 1,528 | $4K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 60 | $4K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,411 | $4K |
| 99195 | <1% | 616 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 398 | $3K |
| 97802 | <1% | 63 | $3K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $3K |
| 84153 | <1% | 1,585 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 12,128 | $3K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 72 | $3K |
| 95115 | <1% | 163 | $3K | |
| 86706 | <1% | 1,038 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,834 | $3K |
| 51702 | <1% | 29 | $3K | |
| 86704 | <1% | 830 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 44 | $2K |
| 74178 | <1% | 14 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 311 | $2K |
| 96417 | <1% | 56 | $2K | |
| 17110 | <1% | 16 | $2K | |
| 94726 | <1% | 87 | $2K | |
| 90656 | <1% | 181 | $2K | |
| 20610 | <1% | 17 | $2K | |
| 83615 | <1% | 914 | $2K | |
| 82378 | <1% | 1,049 | $2K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 17 | $2K |
| 87522 | Neg quan hep c or qual rna | <1% | 192 | $2K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 16 | $2K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 320 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,701 | $2K |
| 93325 | <1% | 83 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,139 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,429 | $2K |
| 81000 | <1% | 347 | $1K | |
| 99173 | <1% | 2,910 | $1K | |
| 94729 | <1% | 87 | $1K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 19 | $1K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 347 | $1K |
| 73110 | <1% | 75 | $1K | |
| 72110 | <1% | 75 | $1K | |
| 85004 | <1% | 748 | $1K | |
| 96161 | <1% | 187 | $1K | |
| 73120 | <1% | 82 | $1K | |
| 84439 | <1% | 576 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,003 | $1K |
| 84154 | <1% | 145 | $1K | |
| 97602 | <1% | 45 | $1K | |
| 90734 | <1% | 83 | $1K | |
| 82948 | <1% | 708 | $1K | |
| 85652 | <1% | 559 | $1K | |
| 82677 | <1% | 60 | $980.12 | |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | <1% | 18 | $959.39 |
| 90694 | <1% | 338 | $900.58 | |
| 82397 | <1% | 569 | $850.34 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 3,575 | $839.17 |
| 93017 | <1% | 16 | $805.22 | |
| 84156 | <1% | 1,222 | $802.34 | |
| 82105 | <1% | 94 | $780.19 | |
| 36591 | <1% | 304 | $624.08 | |
| 87529 | <1% | 40 | $614.03 | |
| 93926 | <1% | 15 | $580.34 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 81 | $559.88 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 12 | $546.28 |
| 84144 | <1% | 25 | $506.69 | |
| 83516 | <1% | 196 | $504.86 | |
| 82607 | <1% | 168 | $502.76 | |
| 73620 | <1% | 26 | $500.42 | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 12 | $458.14 |
| 85378 | <1% | 62 | $436.92 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 55 | $434.49 |
| 81002 | <1% | 222 | $398.48 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 31 | $396.40 |
| 86708 | <1% | 201 | $386.77 | |
| 87040 | <1% | 20 | $386.05 | |
| 73090 | <1% | 38 | $378.20 | |
| 90732 | <1% | 39 | $365.79 | |
| 87430 | <1% | 20 | $351.40 | |
| 82784 | <1% | 137 | $348.84 | |
| 94060 | <1% | 15 | $348.79 | |
| 84550 | <1% | 121 | $345.94 | |
| A6449 | Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | <1% | 1,486 | $344.69 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 211 | $332.54 |
| 82465 | <1% | 427 | $322.33 | |
| 84155 | <1% | 296 | $315.74 | |
| 80069 | <1% | 234 | $313.80 | |
| 82310 | <1% | 856 | $308.95 | |
| 82040 | <1% | 855 | $307.89 | |
| 85007 | <1% | 371 | $300.56 | |
| 73030 | <1% | 31 | $298.84 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 584 | $287.52 |
| 86431 | <1% | 174 | $229.33 | |
| 90634 | <1% | 74 | $227.80 | |
| 82803 | <1% | 19 | $221.04 | |
| 73060 | <1% | 12 | $211.88 | |
| 84480 | <1% | 83 | $208.63 | |
| 90700 | <1% | 12 | $208.16 | |
| 90723 | <1% | 29 | $201.90 | |
| 84165 | <1% | 271 | $201.60 | |
| 90633 | <1% | 12 | $197.00 | |
| 92511 | <1% | 43 | $185.52 | |
| 83883 | <1% | 75 | $170.04 | |
| 85379 | <1% | 17 | $150.60 | |
| 86300 | <1% | 87 | $130.14 | |
| 72170 | <1% | 12 | $116.82 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 966 | $113.54 |
| 90714 | <1% | 29 | $111.75 | |
| 82330 | <1% | 17 | $109.44 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 210 | $105.35 |
| 84436 | <1% | 83 | $99.40 | |
| 86320 | <1% | 34 | $93.48 | |
| 84479 | <1% | 83 | $91.90 | |
| 90648 | <1% | 109 | $88.28 | |
| 90658 | <1% | 52 | $84.64 | |
| 87186 | <1% | 100 | $81.09 | |
| 73502 | <1% | 18 | $75.52 | |
| 83718 | <1% | 69 | $68.24 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 35 | $66.69 |
| 74019 | <1% | 12 | $55.22 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 626 | $51.20 |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | <1% | 526 | $47.85 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 29 | $44.99 |
| J3490 | Unclassified drugs | <1% | 505 | $42.81 |
| 86705 | <1% | 20 | $36.78 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 18 | $35.92 |
| 86709 | <1% | 20 | $35.19 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 84 | $34.88 |
| 82044 | <1% | 20 | $34.46 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 478 | $32.14 |
| 82746 | <1% | 22 | $30.64 | |
| 85048 | <1% | 74 | $15.90 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,779 | $9.88 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 81 | $9.68 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 199 | $3.89 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,547 | $2.24 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 246 | $1.80 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 33 | $1.16 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 79 | $1.04 |
| 96376 | 0% | 31 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 85 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 70 | $0.00 |
| 90716 | 0% | 35 | $0.00 | |
| 90698 | 0% | 21 | $0.00 | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 0% | 22 | $0.00 |
| 90680 | 0% | 43 | $0.00 | |
| 80320 | 0% | 18 | $0.00 | |
| J0613 | Injection, calcium gluconate (wg critical care), not therapeutically equivalent to j0612, 10 mg | 0% | 20 | $0.00 |
| 36514 | 0% | 21 | $0.00 | |
| 90657 | 0% | 13 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 42 | $0.00 |
| G0009 | Administration of pneumococcal vaccine | 0% | 20 | $0.00 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 46 | $0.00 |
| 90707 | 0% | 16 | $0.00 | |
| 99152 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPROCTOR, JAMES (SVP/CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Shelby County Health Care Corporation | Memphis, TN | $448K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.